Additional file 1: Table S1. of DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas

Sample size and diffuse glioma subsets of various cohorts used in this study. Table S2. List of differentially methylated CpGs between LGG IDH mutant and WT used as PAM input in the training (TCGA) set. Table S3A. List of the 14 CpG methylation signatures for LGG IDH mutant versus IDH WT in the test set (TCGA) and validation set (GSE48462). Table S3B. List of the 14 CpG methylation signatures for oligodendroglioma (ODG) versus diffuse astrocytoma (DA) in the test set (TCGA) and validation set (GSE48462). Table S4. List of differentially methylated CpGs between oligodendroglioma and diffuse astrocytoma used as PAM input in the training (TCGA) set. Table S5. List of 259 differentially methylated CpG probes between GBM IDH mutant and WT used as PAM input in the training (TCGA) set. Table S6. Molecular analysis of discordant samples identified by CpG methylation signatures. Table S7A. Molecular status for IDH, TP53, ATRX, and 1p/19q in LGG samples from TCGA used in this study. Table S7B. Molecular status for IDH, TP53, ATRX, and 1p/19q in LGG samples from GSE58218 used in this study. Table S7C. Molecular status for IDH, TP53, ATRX, and 1p/19q in LGG samples from GSE48462 used in this study. Table S8. Patient IDs of the discordant samples derived from all datasets used in this study. Table S9A. Molecular status of IDH, TP53, ATRX, EGFR, and PTEN in GBM samples from TCGA dataset used in this study. Table S9B. Molecular status of IDH, TP53, ATRX, EGFR, and PTEN in GBM samples from GSE38278 dataset used in this study. (ZIP 1601Â kb)